Disease · MONDO_0006651

anterior uveitis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. anterior uveitis. Diseases, record MONDO_0006651. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006651

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: anterior uveitis; Open Targets
Open Targets ID: MONDO_0006651; Open Targets
Other names: Anterior uveitis [Ambiguous], Anterior uveitis, NOS, Uveitis, Anterior, anterior uveitis (disease); Open Targets
Disease Ontology: DOID:1407; Disease Ontology
MeSH: D014606; MeSH
NCI Thesaurus: C35109; NCI Thesaurus
Orphanet: ORPHA:280886; Orphanet
Highest stage of its drugs: Approval, for 3 of its 28 drugs, from DailyMed; Open Targets

Drugs28

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DIFLUPREDNATE	CHEMBL1201749	Small molecule	Approval	DailyMed	5	4	4	Drugs and targets
LOTEPREDNOL ETABONATE	CHEMBL1200865	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
TOBRAMYCIN	CHEMBL1747	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
SIVELESTAT	CHEMBL76688	Small molecule	Preapproval	TTD	1	0	0	Drugs and targets
DAZDOTUFTIDE	CHEMBL5095261	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
PREDNISOLONE ACETATE	CHEMBL1152	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
REPROXALAP	CHEMBL4297210	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ETHAMBUTOL	CHEMBL44884	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ISONIAZID	CHEMBL64	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
PYRAZINAMIDE	CHEMBL614	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets

1 to 10 of 28

See all 28 drugs

Targets5

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	12	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
ELANE	Neutrophil elastase	1	Leukocyte elastase inhibitor	Preapproval	https://conductscience.org/library/genes/1991	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	1	FK506-binding protein 1A inhibitor	Phase 1	https://conductscience.org/library/genes/2280	Drugs and targets
PPP3CA	Protein phosphatase 3 catalytic subunit alpha	1	Serine/threonine protein phosphatase 2B catalytic subunit, alpha isoform inhibitor	Phase 3	https://conductscience.org/library/genes/5530	Drugs and targets
TNF	Tumor necrosis factor	1	TNF-alpha inhibitor	Unknown	https://conductscience.org/library/genes/7124	Drugs and targets

Trials18

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03131154	SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.	Phase 3	123	2025-02-10	Non-infectious Anterior Uveitis	REPROXALAP	Its record names the disease	ClinicalTrials.gov
NCT01201798	Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis	Phase 3	111	2012-11-15	Endogenous Anterior Uveitis	DIFLUPREDNATE, PREDNISOLONE ACETATE	Its record names the disease	ClinicalTrials.gov
NCT03586284	Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes	Phase 2/3	51	2026-02-10	Cytomegalovirus Anterior Uveitis	GANCICLOVIR, VALGANCICLOVIR	Its record names the disease	ClinicalTrials.gov
NCT03584724	Assessment of the Anti-inflammatory Effects of Norflo Oro in Acute Relapses of HLA-B27 Associated Autoimmune Uveitis	Early phase 1	49	2022-03-28	Uveitis	CURCUMIN	Its record names the disease	ClinicalTrials.gov
NCT02406209	A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis	Phase 2	45	2023-03-27	Non-infectious Anterior Uveitis	PREDNISOLONE ACETATE, REPROXALAP	Its record names the disease	ClinicalTrials.gov
NCT02482129	Proof of Concept Study to Evaluate Safety and Efficacy of LME636 in the Treatment of Acute Anterior Uveitis	Phase 2	45	2017-08-28	Acute Anterior Uveitis	DEXAMETHASONE, LICAMINLIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT04222712	A Study to Evaluate TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis	Phase 1/2	16	2023-10-05	Non-infectious Anterior Uveitis	DAZDOTUFTIDE	Its record names the disease	ClinicalTrials.gov
NCT05042609	TRS4Vision - A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma	Phase 3	142		Non-infectious Anterior Uveitis, Uveitic Glaucoma	DAZDOTUFTIDE	Its record names the disease	ClinicalTrials.gov
NCT07513623	Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II	Phase 2	117		Cytomegalovirus (CMV), Anterior Uveitis, Infectious Uveitis, CMV Infection	GANCICLOVIR, VALGANCICLOVIR	Its record names the disease	ClinicalTrials.gov
NCT04117698	Multicenter, Randomized Study Evaluating the Value of Antitubercular Treatment During Recurent Anterior Uveitis (URBA)	Phase 3	116		Uveitis, Anterior	ETHAMBUTOL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 18

See all 18 trials

Comparisons in its trials9

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
ADX-102 Ophthalmic Solution (0.5%) vs Vehicle Ophthalmic Solution: deaths from any cause	0 of 61	0 of 62	123	NCT03131154	Trial comparisons
ADX-102 Ophthalmic Solution (0.5%) vs Vehicle Ophthalmic Solution: serious adverse events	1 of 61	2 of 62	123	NCT03131154	Trial comparisons
Durezol vs Pred Forte: serious adverse events	2 of 56	0 of 54	110	NCT01201798	Trial comparisons
Norflo Oro vs Placebo for Norflo Oro: deaths from any cause	0 of 20	0 of 24	44	NCT03584724	Trial comparisons
Norflo Oro vs Placebo for Norflo Oro: serious adverse events	3 of 20	0 of 24	44	NCT03584724	Trial comparisons
LME636 vs Dexamethasone: Number of Responders at Day 15	14 of 25	9 of 10	35	NCT02482129	Trial comparisons
TRS01 Low Dose vs TRS01 High Dose: deaths from any cause	0 of 8	0 of 8	16	NCT04222712	Trial comparisons
TRS01 Low Dose vs TRS01 High Dose: Assessment of Both Systemic and Ocular Adverse Events	2 of 8	5 of 8	16	NCT04222712	Trial comparisons
TRS01 Low Dose vs TRS01 High Dose: serious adverse events	0 of 8	0 of 8	16	NCT04222712	Trial comparisons

Papers from its trials7

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41485727	RESULT	1	PubMed
35353651	DERIVED	1	PubMed
32955967	DERIVED	1	PubMed
31862739	DERIVED	1	PubMed
24677110	DERIVED	1	PubMed
22465364	DERIVED	1	PubMed
20809807	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006651

GET https://conductscience.org/api/diseases/v1/MONDO_0006651/drugs?page=2

API reference For AI assistants